EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 3.0

Pharmacokinetics, Safety and Tolerability of Intravenous Lenzilumab, an Anti-GM-CSF Monoclonal Antibody Drug, in Healthy Korean Subjects

Jaegu Kang iD, Sungyeun Bae iD, Kyung-Sang Yu iD, SeungHwan Lee iD

Drug Design, Development and Therapy · 2025-10 · Volume 19 · 9227-9234

DOI: 10.2147/dddt.s550126 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Drug Design, Development and Therapy, 2025-10. Verfasst von Jaegu Kang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Granulocyte-Macrophage Colony-Stimulating Factor, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Granulocyte-Macrophage Colony-Stimulating FactorAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedHumansMaleDouble-Blind MethodAdultHealthy VolunteersFemaleYoung AdultDose-Response Relationship, DrugRepublic of KoreaAdministration, IntravenousInfusions, Intravenous

Stichwörter der Autor:innen

COVID-19cytokine release syndromegranulocyte-macrophage colony-stimulating factormonoclonal antibodypharmacokineticsphase 1 clinical trial

Substanzen

Granulocyte-Macrophage Colony-Stimulating FactorAntibodies, MonoclonalAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.

ORCID-Profile: Jaegu Kang, Sungyeun Bae, Kyung-Sang Yu, SeungHwan Lee

Zitieren

APA

Kang, J., Bae, S., Yu, K. S., & Lee, S. (2025). Pharmacokinetics, Safety and Tolerability of Intravenous Lenzilumab, an Anti-GM-CSF Monoclonal Antibody Drug, in Healthy Korean Subjects. Drug Design, Development and Therapy, Volume 19, 9227-9234. https://doi.org/10.2147/dddt.s550126

Vancouver

Kang J, Bae S, Yu KS, Lee S. Pharmacokinetics, Safety and Tolerability of Intravenous Lenzilumab, an Anti-GM-CSF Monoclonal Antibody Drug, in Healthy Korean Subjects. Drug Design, Development and Therapy. 2025;Volume 19:9227-9234. doi:10.2147/dddt.s550126

BibTeX
@article{Kang2025,
  author = {Kang, Jaegu and Bae, Sungyeun and Yu, Kyung-Sang and Lee, SeungHwan},
  title = {Pharmacokinetics, Safety and Tolerability of Intravenous Lenzilumab, an Anti-GM-CSF Monoclonal Antibody Drug, in Healthy Korean Subjects},
  journal = {Drug Design, Development and Therapy},
  year = {2025},
  volume = {Volume 19},
  pages = {9227--9234},
  doi = {10.2147/dddt.s550126}
}
Kostenlos starten →